Skip to Main Content

Try STAT+ TODAY

EpiPen

Most Read

Pharmalot Ed Silverman

Pension funds push for Mylan to remove chairman and a director

Exclusive Ike Swetlitz

Mylan offered EpiPen discounts to states in exchange for privileged status, documents show

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Merck and Scottish government conspired to trash environmental study

Pharmalot Ed Silverman

Some states consider making it easier to dispense EpiPen alternatives

Pharmalot Ed Silverman

Lawmakers threaten Mylan with a subpoena for EpiPen documents

Pharmalot Ed Silverman

FTC probes Mylan for possible antitrust violations involving EpiPen

Pharmalot Ed Silverman

An EpiPen rival will return, but with a questionable strategy

Pharmalot Ed Silverman

Mylan refuses to testify at Senate hearing about EpiPen rebates to Medicaid

All Coverage

Pharmalot Ed Silverman

Hospitals are itching for a share of the Mylan settlement over Medicaid rebates

Pharmalot Ed Silverman

West Virginia AG vows to reject ‘woefully deficient’ Mylan deal with the feds

advertisement

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Valeant looks to sell Salix to lessen debt load

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Drug stocks hurt by fears that price hikes are abating

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Senator to hold hearing on Mylan’s Medicaid settlement

Pharmalot Ed Silverman

An EpiPen alternative is about to return to your local pharmacy

Pharmalot Ed Silverman

EpiPen prescriptions continue to climb, but market share dropped

Pharmalot Ed Silverman

Elizabeth Warren criticizes feds for a ‘shamefully weak’ deal with Mylan

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month

The Pharmalot View Ed Silverman

Health officials should reject latest gambit by EpiPen maker to feed at the public trough

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Some docs say more patients want do-it-yourself EpiPens

Pharmalot Ed Silverman

Mylan to pay $465 million to settle claims of shortchanging Medicaid

Pharmalot Ed Silverman

Mylan overcharged Medicaid for EpiPen for years, despite warnings

First Opinion Jennifer Brokaw

Cheap EpiPen alternative risks patients’ lives. I’ve seen it myself

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Chicago can proceed with lawsuit against opioid drug makers

Pharmalot Ed Silverman

Feds slam Mylan for misclassifying EpiPen, with ‘financial consequences’ to Medicaid

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Novo Nordisk cutting 1,000 jobs amid diabetes drug price war